Dexcel-pharma Limited

Dexcel Pharma Ltd, based in Daventry, UK, is a large holding company with an active status, celebrating 30 years since its founding in 1994. Employing 21 people, the company holds £17,682,217 in assets and generates £21,547,541 in yearly revenue. It’s managed by three directors and owned by one individual, with a real registered address. The company regularly imports essential oils and perfumes (14 months of imports) and irregularly exports pharmaceutical products (1 month of exports).

Dexcel Pharma operates as a privately owned pharmaceutical company, developing, manufacturing, and commercializing innovative and generic products globally. Its website highlights a diversified portfolio, including branded prescription drugs, over-the-counter medications, and generic pharmaceuticals. The company’s activities span research and development, manufacturing, and commercialization, with a focus on markets like the United States, Israel, Germany, the UK, and Austria. The website also points to a piano restoration division, 1066 Pianos, which is a surprising, yet fascinating, side venture.

Financially, Dexcel Pharma shows some concerning trends. While current assets increased by 10% to £18 million, net assets significantly increased by 31% to £26 million. However, bank borrowings increased by 35% to £3.5 million, and cash bank on hand decreased by 25% to £2.4 million. The company’s size (meeting two of three conditions for a large company) suggests it’s a substantial player, but the increase in debt warrants attention. The company’s auditor, MHA, has reported nothing to note in their opinion. Despite the increase in debt, the company’s revenue is still high, and it’s likely that the company is investing in expansion.

Registered in England/Wales under the registration number 02963398, with a registered address at NN11 8PB, Daventry, Northamptonshire, 7 Sopwith Way, Drayton Fields Industrial Estate.

WARNING:The numbers have been rounded for simplicity and may be inaccurate.Please, refer to the latest financial report for verification.